1. Concise review: how do red blood cells born, live, and die?

   • J.L. Vives Corrons
   • L. Berga Casafont
   • E. Feliu Frasnedo

   Review Article 03 August 2021 Pages: 2425 - 2433

   

2. Time and residual hematopoiesis are crucial for PNH clones escape in hepatitis-associated aplastic anemia

   • Wenrui Yang
   • Xin Zhao
   • Fengkui Zhang

   Original Article 16 July 2021 Pages: 2435 - 2441

3. Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study

   • Lalita Norasetthada
   • Somchai Wongkhantee
   • for the Thai Aplastic Anemia Study Group

   Original Article Open access 16 July 2021 Pages: 2443 - 2452

   

4. SIRT1 single-nucleotide polymorphisms are associated with corticosteroid sensitivity in primary immune thrombocytopenia patients

   • Shuwen Wang
   • Xiaoyu Zhang
   • Xiang Hu

   Original Article 16 July 2021 Pages: 2453 - 2462

   

5. Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype

   • Negin Shokrgozar
   • Mehran Karimi
   • Nargess Arandi

   Original Article 29 July 2021 Pages: 2463 - 2469

   

6. Digital thermography and vascular involvement in β-thalassemia intermedia

   • Farah Abdulhai
   • Miran A. Jaffa
   • Marwan M. Refaat

   Original Article 08 July 2021 Pages: 2471 - 2477

   

7. Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia

   • Ryujiro Hara
   • Makoto Onizuka
   • Kiyoshi Ando

   Original Article 11 July 2021 Pages: 2479 - 2486

   

8. Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL

   • Nupur Das
   • Ritu Gupta
   • Lalit Kumar

   Original Article 08 July 2021 Pages: 2487 - 2500

   

9. Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)

   • Neda Alrawashdh
   • Joann Sweasy
   • Ivo Abraham

   Original Article 19 July 2021 Pages: 2501 - 2512

   

10. Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database

    • Radowan Elnair
    • Moataz Ellithi
    • Robert G. Bociek

    Original Article 19 July 2021 Pages: 2513 - 2519

    

11. N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution

    • Victor H. Jimenez-Zepeda
    • Holly Lee
    • Nizar J. Bahlis

    Original Article 21 July 2021 Pages: 2521 - 2527

    

12. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

    • Won Seog Kim
    • Yasuhiro Oki
    • Helen E. Heslop

    Original Article 24 July 2021 Pages: 2529 - 2539

    

13. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

    • Marta Krejci
    • Ludek Pour
    • Zdenek Kral

    Original Article 26 July 2021 Pages: 2541 - 2546

14. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi

    • Armando Santoro
    • Rita Mazza
    • Francesco Merli

    Original Article 30 July 2021 Pages: 2547 - 2556

    

15. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment

    • Jun Kong
    • Ya-zhen Qin
    • Hao Jiang

    Original Article 19 July 2021 Pages: 2557 - 2566

    

16. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

    • Hyoung Soo Choi
    • Junshik Hong
    • Soo-Mee Bang

    Original Article 30 July 2021 Pages: 2567 - 2574

    

17. Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients

    • Judith Strapatsas
    • Elena Calina Barbulescu
    • Ulrich Germing

    Original Article Open access 29 July 2021 Pages: 2575 - 2584

    

18. Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion

    • Neal Shah
    • Kevin Rakszawski
    • Kentaro Minagawa

    Original Article 29 July 2021 Pages: 2585 - 2592

    

19. Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia

    • Ruihua Mi
    • Lin Chen
    • Xudong Wei

    Original Article Open access 27 July 2021 Pages: 2593 - 2601

    

20. Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy

    • Olivier Ballo
    • Fagr Eladly
    • Christian H. Brandts

    Original Article Open access 25 July 2021 Pages: 2603 - 2611

    

21. Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan

    • Kensuke Matsuda
    • Taisuke Jo
    • Mineo Kurokawa

    Original Article 26 July 2021 Pages: 2613 - 2619

    

22. Circulating miR-455-3p, miR-5787, and miR-548a-3p as potential noninvasive biomarkers in the diagnosis of acute graft-versus-host disease: a validation study

    • Jamshid Motaei
    • Mohammad Amin Kerachian
    • Marjan Yaghmaie

    Original Article 11 July 2021 Pages: 2621 - 2631

    

23. Sustained remission of giant pancreatic plasmacytoma with daratumumab

    • Satoshi Ichikawa
    • Eijiro Furukawa
    • Hideo Harigae

    Letter to the Editor 18 June 2020 Pages: 2633 - 2634

    

24. A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type

    • Mathias T. Rosenfeldt
    • Elena M. Hartmann
    • Ioannis Anagnostopoulos

    Letter to the Editor Open access 19 July 2020 Pages: 2635 - 2637

    

25. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation

    • Yuichi Ikeda
    • Jun Yamanouchi
    • Katsuto Takenaka

    Letter to the Editor 16 July 2020 Pages: 2639 - 2641

    

26. A novel mutation in the JAK2 gene (R588S) in a Chinese patient with erythrocytosis

    • Xiu-Peng Ye
    • Jing Wang
    • Shen Bao

    Letter to the Editor 31 July 2020 Pages: 2643 - 2645

    

27. HHV-8 negative PEL-like lymphoma follicular helper T type in a non-HIV infected elderly

    • Keisuke Kidoguchi
    • Masumi Uchino
    • Koichi Ohshima

    Letter to the Editor 17 August 2020 Pages: 2647 - 2648

    

28. Collision diffuse large B cell lymphoma and myeloid sarcoma in the liver

    • Andrea Marra
    • Giovanni Martino
    • Stefano Ascani

    Letter to the Editor 28 August 2020 Pages: 2649 - 2651

    

29. CD30 expression: a diagnostic pitfall for primary cutaneous gamma delta T cell lymphoma

    • Karen H. K. Tang
    • Rex Au-Yeung
    • Yok-lam Kwong

    Letter to the Editor 28 August 2020 Pages: 2653 - 2657

    

30. High density of IgG4-secreting plasma cells in the fibrotic tissue from a surgically resected tracheal ring impaired by complex subglottic stenosis post-tracheostomy as immune expression of a T_h2 response due to severe COVID-19

    • Luca Roncati
    • Giuliano Bergonzini
    • Stefania Corrado

    Letter to the Editor 28 August 2020 Pages: 2659 - 2660

    

31. Persistent pseudo-Pelger-Huët anomaly

    • Süreyya Savaşan
    • Steven Buck
    • Janet Poulik

    Letter to the Editor 29 August 2020 Pages: 2661 - 2663

    

32. A novel case of γδ T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis

    • Satoshi Ichikawa
    • Tohru Fujiwara
    • Hideo Harigae

    Letter to the Editor 31 August 2020 Pages: 2665 - 2668